Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Gross Margin (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Gross Margin for 17 consecutive years, with 69.97% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 168.0% to 69.97% in Q4 2025 year-over-year; TTM through Dec 2025 was 69.93%, a 4.0% increase, with the full-year FY2025 number at 69.93%, up 4.0% from a year prior.
  • Gross Margin was 69.97% for Q4 2025 at Myriad Genetics, roughly flat from 69.91% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 74.66% in Q2 2021 to a low of 50.06% in Q4 2022.
  • A 5-year average of 62.98% and a median of 69.98% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: plummeted -12157bps in 2022, then soared 9177bps in 2023.
  • Myriad Genetics' Gross Margin stood at 71.52% in 2021, then crashed by -170bps to 50.06% in 2022, then surged by 183bps to 41.71% in 2023, then skyrocketed by 72bps to 71.65% in 2024, then fell by -2bps to 69.97% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Gross Margin are 69.97% (Q4 2025), 69.91% (Q3 2025), and 71.23% (Q2 2025).